Title: The Laboratory
Robotics Interest Group (LRIG) seminars
Date: Wednesday, March 30, 2005
Time: 5 p.m. - 8 p.m.
Location: Millennium Auditorium, 35 Landsdowne Street, Cambridge
Contact : Richard Shamon PhD, 617-566-0511
5:00 PM 6:00 PM Social Hour (appetizers and desserts)
6:00 PM - 8:00 PM Presentations (4 Biotech / Pharma SPEAKERS)
6:00 pm
Title: Fully Automated
Solubility Determination
1st Speaker: Dr. Liping Zhou,
Novartis Institute for Biomedical Research
The drug discovery process
have changed considerably during the past decades as more and more
pharmaceutical companies realized the importance of understanding the ADME
properties in early discovery to decrease the cost and the high drug candidate
attrition rate in development and have already done so. Of them, solubility and
rate of dissolution are two critical factors as they affect both in vitro and
in vivo assay results.
Poor solubility is one of the major causes of
drug development failure as drug substances have to be dissolved before they
can be absorbed. Dosing poorly soluble compounds in pharmacological testing is
very risky as it commonly fails in deriving a correlation between dose and in
vivo efficacy.
Different approaches (e.g. in silico,
kinetic, equilibrium solubility) are utilized in parallel to deal with the
solubility and dissolution issues occurring at the different stages in drug
discovery, with a balance in the quality of the data, the throughout, the
turn-around time and the compound consumption.
6:30 pm
Title: Echo 380 and Echo 550
Compound Reformater
2nd Speaker: Dr. Paul
Ventura, LabCyte
Focused acoustic auditing and dispensing is
proving to be of significant value to the life sciences research community,
particularly in the area of compound library characterization and replication.
Acoustic interregation of 384 and 1536 source plates can yield hydration levels
in DMSO and volume data to aid researchers in evaluting the state of their
libraries. In addition, compounds can be transferred in nanoliter quantities,
saving dilution plate steps and without using costly disposable pipet tips or
wash solvents since this is truly a "touchless" transfer.The
principles behind this remarkable new technology will be explained, as well as
some preliminary data on the effect of various compounds on this technique.
7:00 pm
Title: New Drug Screening for Cellular Protection Against Oxidative Insult
and Viral Infection
3rd Speaker: Dr. Grace
Wong, Founder & CSO of ActoKine Therapeutics
ActoKine
Therapeutics has identified ActoKine-1 (AK-1) that protects cells against acute
radiation damage. AK-1 enhanced the recovery of blood cells and the survival of
bone marrow and gut cells after exposure to radiation. AK-1 has shown no
toxicity in mice or monkeys. At this time there are no drugs available for
radioprotection. AK-1 has the potential to fill an urgent need for
counterterrorism applications in Homeland defense and the military, as well as
protecting emergency and disaster response personnel from radiation hazards.
ActoKine has also identified AK-2, which can provide cellular protection
against viral infections. Very importantly, AK-2 is effective against a wide
spectrum of known viruses and possibly emerging new viruses, as well.
Using CytoKey and
CytoKill technologies, Actokine Therapeutics is dedicated to identifying
master control genes regulated by AK-1 and AK-2. Actokine
Therapeutics has initiated a screening program using rapid and gene specific
methodologies to discover small molecule compounds that mimic the biological actions
of AK-1 and AK-2. ActoKine has identified specific pathways and biomarkers that
are regulated by AK-1 and AK-2 in vitro and in vivo and are readily
targetable for high through-put screening. Using AK-1 and AK-2 inducible master
biomarkers, ActoKine will initially screen for AK-1 and AK-2 mimetics among
existing drugs (failed, patented, or generic). The successful identification of
a known drug will preclude the need for some or all of the approval process and
create a viable solution in an accelerated timeframe.
Speaker
Biography: Dr. Grace Wong has worked for
Genentech, Millennium, AstraZeneca and Serono on new drug discovery in a
variety of therapeutic areas. Dr. Wong did a PhD at The Walter and Eliza Hall
Institute of Medical Research in Australia. In the US, Dr. Wong did a postdoc
with Dr. David Goeddel at Genentech and she advanced basic research discoveries
to product development in 1993. In 1996, Dr. Wong became the Head of Apoptosis
Research at Millennium Pharmaceuticals and identified potential drug resistance
genes using functional genomics.
In 1998, she joined AstraZeneca as Section Head of Molecular Genetics and
identified potential genes for Alzheimer's disease. Since AstraZeneca was
moving to Delaware, Dr. Wong joined Serono in 1999 as Head of Functional
Genomics and Director of Cytokine Genomics. She created 17 unique cDNA
libraries for discovery of new cytokine genes and discovered several novel
functions of cytokines for obesity and women's health. She has been awarded 13
scholarships and received 5 Recognition Awards from Genentech. She was invited
to present at 139 international conferences including the Nobel Symposium
(Sweden, 1994). She has published 87 papers and filed 27 patents (11 issued).
Seven of her publications (3 Nature, 1 Science, and 3 Cell) received 500-900
citations.
Dr. Wong has founded Actokine Therapeutics (www.actokine.com) which will focus on (1) drug rescue (2)
drug indication switch and (3) drug advancements for biodefense projects
(radioprotection against dirty bomb and protection against a broad spectrum of
virus). She has also founded Student Vision for helping the growth of students
of all ages in biotech science (www.studentvision.org).
7:30 pm
Title: Pre-Clinical Profiling
4th Speaker: Dr. Laszlo Urban, Novartis Institute for Biomedical Research
Recent development in in vitro ADMET and
pharmacological screening technologies allowed the implementation of early
profiling assays to aid drug discovery. Data generated by these assays allow
scientists to characterize compounds during lead selection and lead
optimization phase and aid chemists to address drug-like properties and safety
issues parallel with optimization for the primary target. Critical analysis of
the profiling assay portfolio, capacity requirements, timing of assays and data
interpreation/impact on drug discovery will be addressed in this presentation.
http://www.lab-robotics.org